Literature DB >> 21624403

Protein aggregate spreading in neurodegenerative diseases: problems and perspectives.

Seung-Jae Lee1, Hee-Sun Lim, Eliezer Masliah, He-Jin Lee.   

Abstract

Progressive accumulation of specific protein aggregates is a defining feature of many major neurodegenerative diseases, including Alzheimer's disease, Parkinson's disease, fronto-temporal dementia, Huntington's disease, and Creutzfeldt-Jakob disease (CJD). Findings from several recent studies have suggested that aggregation-prone proteins, such as tau, α-synuclein, polyglutamine-containing proteins, and amyloid-β, can spread to other cells and brain regions, a phenomenon considered unique to prion disorders, such as CJD and bovine spongiform encephalopathy. Cell-to-cell propagation of protein aggregates may be the general underlying principle for progressive deterioration of neurodegenerative diseases. This may also have significant implications in cell replacement therapies, as evidenced by the propagation of α-synuclein aggregates from host to grafted cells in long-term transplants in Parkinson's patients. Here, we review recent progress in protein aggregate propagation in experimental model systems and discuss outstanding questions and future perspectives. Understanding the mechanisms of this pathological spreading may open the way to unique opportunities for development of diagnostic techniques and novel therapies for protein misfolding-associated neurodegenerative diseases.
Copyright © 2011 Elsevier Ireland Ltd and the Japan Neuroscience Society. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21624403      PMCID: PMC3912578          DOI: 10.1016/j.neures.2011.05.008

Source DB:  PubMed          Journal:  Neurosci Res        ISSN: 0168-0102            Impact factor:   3.304


  104 in total

1.  Neural activity controls the synaptic accumulation of alpha-synuclein.

Authors:  Doris L Fortin; Venu M Nemani; Susan M Voglmaier; Malcolm D Anthony; Timothy A Ryan; Robert H Edwards
Journal:  J Neurosci       Date:  2005-11-23       Impact factor: 6.167

2.  Activity-related redistribution of presynaptic proteins at the active zone.

Authors:  J-H Tao-Cheng
Journal:  Neuroscience       Date:  2006-06-06       Impact factor: 3.590

3.  Synaptic activity regulates interstitial fluid amyloid-beta levels in vivo.

Authors:  John R Cirrito; Kelvin A Yamada; Mary Beth Finn; Robert S Sloviter; Kelly R Bales; Patrick C May; Darryle D Schoepp; Steven M Paul; Steven Mennerick; David M Holtzman
Journal:  Neuron       Date:  2005-12-22       Impact factor: 17.173

4.  Alzheimer's disease beta-amyloid peptides are released in association with exosomes.

Authors:  Lawrence Rajendran; Masanori Honsho; Tobias R Zahn; Patrick Keller; Kathrin D Geiger; Paul Verkade; Kai Simons
Journal:  Proc Natl Acad Sci U S A       Date:  2006-07-12       Impact factor: 11.205

5.  The most infectious prion protein particles.

Authors:  Jay R Silveira; Gregory J Raymond; Andrew G Hughson; Richard E Race; Valerie L Sim; Stanley F Hayes; Byron Caughey
Journal:  Nature       Date:  2005-09-08       Impact factor: 49.962

6.  Detection of oligomeric forms of alpha-synuclein protein in human plasma as a potential biomarker for Parkinson's disease.

Authors:  Omar M A El-Agnaf; Sultan A Salem; Katerina E Paleologou; Martin D Curran; Mark J Gibson; Jennifer A Court; Michael G Schlossmacher; David Allsop
Journal:  FASEB J       Date:  2006-03       Impact factor: 5.191

7.  Exogenous induction of cerebral beta-amyloidogenesis is governed by agent and host.

Authors:  Melanie Meyer-Luehmann; Janaky Coomaraswamy; Tristan Bolmont; Stephan Kaeser; Claudia Schaefer; Ellen Kilger; Anton Neuenschwander; Dorothee Abramowski; Peter Frey; Anneliese L Jaton; Jean-Marie Vigouret; Paolo Paganetti; Dominic M Walsh; Paul M Mathews; Jorge Ghiso; Matthias Staufenbiel; Lary C Walker; Mathias Jucker
Journal:  Science       Date:  2006-09-22       Impact factor: 47.728

8.  Proteolytic cleavage of extracellular secreted {alpha}-synuclein via matrix metalloproteinases.

Authors:  Jee Young Sung; Sung Min Park; Choong-Hwan Lee; Ji Won Um; Hyun Jung Lee; Jongsun Kim; Young J Oh; Seung-Taek Lee; Seung R Paik; Kwang Chul Chung
Journal:  J Biol Chem       Date:  2005-04-29       Impact factor: 5.157

9.  Intravesicular localization and exocytosis of alpha-synuclein and its aggregates.

Authors:  He-Jin Lee; Smita Patel; Seung-Jae Lee
Journal:  J Neurosci       Date:  2005-06-22       Impact factor: 6.167

10.  Progressive disruption of cellular protein folding in models of polyglutamine diseases.

Authors:  Tali Gidalevitz; Anat Ben-Zvi; Kim H Ho; Heather R Brignull; Richard I Morimoto
Journal:  Science       Date:  2006-02-09       Impact factor: 63.714

View more
  62 in total

1.  Spreading of Alzheimer's disease inflammatory signaling through soluble micro-RNA.

Authors:  Walter J Lukiw; Peter N Alexandrov; Yuhai Zhao; James M Hill; Surjyadipta Bhattacharjee
Journal:  Neuroreport       Date:  2012-07-11       Impact factor: 1.837

Review 2.  Cellular and molecular biology of optineurin.

Authors:  Hongyu Ying; Beatrice Y J T Yue
Journal:  Int Rev Cell Mol Biol       Date:  2012       Impact factor: 6.813

Review 3.  α-Synuclein aggregation modulation: an emerging approach for the treatment of Parkinson's disease.

Authors:  Sushil K Singh; Aloke Dutta; Gyan Modi
Journal:  Future Med Chem       Date:  2017-06-20       Impact factor: 3.808

4.  Activation of autophagy by rapamycin does not protect oligodendrocytes against protein aggregate formation and cell death induced by proteasomal inhibition.

Authors:  Monika Noack; Christiane Richter-Landsberg
Journal:  J Mol Neurosci       Date:  2014-07-29       Impact factor: 3.444

5.  Evaluation of potential infectivity of Alzheimer and Parkinson disease proteins in recipients of cadaver-derived human growth hormone.

Authors:  David J Irwin; Joseph Y Abrams; Lawrence B Schonberger; Ellen Werber Leschek; James L Mills; Virginia M-Y Lee; John Q Trojanowski
Journal:  JAMA Neurol       Date:  2013-04       Impact factor: 18.302

6.  Replacement of huntingtin exon 1 by trans-splicing.

Authors:  Hansjörg Rindt; Pei-Fen Yen; Christina N Thebeau; Troy S Peterson; Gary A Weisman; Christian L Lorson
Journal:  Cell Mol Life Sci       Date:  2012-07-20       Impact factor: 9.261

7.  Next-generation active immunization approach for synucleinopathies: implications for Parkinson's disease clinical trials.

Authors:  Markus Mandler; Elvira Valera; Edward Rockenstein; Harald Weninger; Christina Patrick; Anthony Adame; Radmila Santic; Stefanie Meindl; Benjamin Vigl; Oskar Smrzka; Achim Schneeberger; Frank Mattner; Eliezer Masliah
Journal:  Acta Neuropathol       Date:  2014-02-14       Impact factor: 17.088

Review 8.  Pharmacophore-based models for therapeutic drugs against phosphorylated tau in Alzheimer's disease.

Authors:  Jangampalli Adi Pradeepkiran; Arubala P Reddy; P Hemachandra Reddy
Journal:  Drug Discov Today       Date:  2018-11-16       Impact factor: 7.851

Review 9.  Extracellular α--synuclein-a novel and crucial factor in Lewy body diseases.

Authors:  He-Jin Lee; Eun-Jin Bae; Seung-Jae Lee
Journal:  Nat Rev Neurol       Date:  2014-01-28       Impact factor: 42.937

10.  Alpha-synuclein promotes early neurite outgrowth in cultured primary neurons.

Authors:  Guangwei Liu; Peng Wang; Xin Li; Yaohua Li; Shengli Xu; Kenji Uéda; Piu Chan; Shun Yu
Journal:  J Neural Transm (Vienna)       Date:  2013-02-27       Impact factor: 3.575

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.